Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
Anteris Technologies Global Corp. (NASDAQ: AVR) has announced the postponement of its Special Meeting of Stockholders from September 11 to September 18, 2025. The virtual meeting will be held at 5:00 p.m. Central time via live webcast.
The postponement aims to provide stockholders additional time to vote on proposals outlined in the Company's August 18 Proxy Statement. The record date remains August 11, 2025. Previously cast votes will remain valid unless changed. The Board unanimously recommends voting FOR the proposals.
Stockholders can vote via Internet or telephone until September 17, while CDI holders must submit their Voting Instruction Forms by September 16. All relevant materials are available on the SEC website and the company's investor relations page.
Anteris Technologies Global Corp. (NASDAQ: AVR) ha annunciato il rinvio della sua Assemblea Straordinaria degli Azionisti dall'11 settembre al 18 settembre 2025. L'assemblea virtuale si terrà alle 17:00, ora centrale, in diretta webcast.
Il rinvio è volto a concedere agli azionisti più tempo per esprimere il proprio voto sulle proposte illustrate nella Proxy Statement della Società del 18 agosto. La data di riferimento resta il 11 agosto 2025. I voti già espressi rimangono validi, salvo modifiche. Il Consiglio raccomanda all'unanimità di VOTARE A FAVORE delle proposte.
Gli azionisti possono votare via Internet o telefono fino al 17 settembre, mentre i titolari di CDI devono inviare i moduli di istruzioni di voto entro il 16 settembre. Tutti i materiali pertinenti sono disponibili sul sito della SEC e nella sezione investor relations della società.
Anteris Technologies Global Corp. (NASDAQ: AVR) ha anunciado el aplazamiento de su Junta Especial de Accionistas del 11 de septiembre al 18 de septiembre de 2025. La reunión virtual se celebrará a las 5:00 p.m., hora central, mediante webcast en directo.
El aplazamiento busca dar a los accionistas más tiempo para votar las propuestas descritas en la Proxy Statement de la Compañía del 18 de agosto. La fecha de registro sigue siendo el 11 de agosto de 2025. Los votos ya emitidos seguirán siendo válidos salvo que se modifiquen. La Junta recomienda por unanimidad VOTAR A FAVOR de las propuestas.
Los accionistas pueden votar por Internet o por teléfono hasta el 17 de septiembre, mientras que los tenedores de CDI deben enviar sus Formularios de Instrucciones de Voto antes del 16 de septiembre. Todos los materiales relevantes están disponibles en la web de la SEC y en la página de relaciones con inversores de la compañía.
Anteris Technologies Global Corp. (NASDAQ: AVR)는 특별 주주총회를 9월 11일에서 2025년 9월 18일로 연기한다고 발표했습니다. 가상 회의는 중앙 표준시 기준 오후 5시에 라이브 웹캐스트로 진행됩니다.
이번 연기는 8월 18일자 회사의 프록시 서류에 명시된 안건들에 대해 주주들이 투표할 시간을 더 제공하기 위한 것입니다. 기준일은 2025년 8월 11일로 변함없습니다. 이미 제출된 투표는 변경하지 않는 한 유효합니다. 이사회는 전원 일치로 안건에 대해 찬성 투표할 것을 권고합니다.
주주들은 9월 17일까지 인터넷 또는 전화로 투표할 수 있으며, CDI 보유자는 9월 16일까지 투표지침서를 제출해야 합니다. 관련 자료는 모두 SEC 웹사이트와 회사의 투자자 관계 페이지에서 확인할 수 있습니다.
Anteris Technologies Global Corp. (NASDAQ: AVR) a annoncé le report de sa Réunion Spéciale des Actionnaires du 11 septembre au 18 septembre 2025. La réunion virtuelle se tiendra à 17h00, heure centrale, par webdiffusion en direct.
Ce report vise à donner aux actionnaires davantage de temps pour voter sur les propositions détaillées dans la Proxy Statement de la Société du 18 août. La date d'enregistrement reste le 11 août 2025. Les votes déjà exprimés restent valables sauf modification. Le Conseil recommande à l'unanimité de VOTER POUR les propositions.
Les actionnaires peuvent voter par Internet ou par téléphone jusqu'au 17 septembre, tandis que les détenteurs de CDI doivent soumettre leurs Formulaires d'Instruction de Vote avant le 16 septembre. Tous les documents pertinents sont disponibles sur le site de la SEC et sur la page relations investisseurs de la société.
Anteris Technologies Global Corp. (NASDAQ: AVR) hat die Verschiebung seiner außerordentlichen Hauptversammlung der Aktionäre vom 11. September auf 18. September 2025 angekündigt. Die virtuelle Versammlung findet um 17:00 Uhr Central Time per Live-Webcast statt.
Die Verschiebung soll den Aktionären mehr Zeit geben, über die in der Proxy Statement der Gesellschaft vom 18. August aufgeführten Vorschläge abzustimmen. Das Stichtagsdatum bleibt der 11. August 2025. Bereits abgegebene Stimmen bleiben gültig, sofern sie nicht geändert werden. Der Vorstand empfiehlt einstimmig, FÜR die Vorschläge zu stimmen.
Aktionäre können bis zum 17. September per Internet oder Telefon abstimmen, während CDI-Inhaber ihre Voting Instruction Forms bis zum 16. September einreichen müssen. Alle relevanten Unterlagen sind auf der Website der SEC und auf der Investor-Relations-Seite des Unternehmens verfügbar.
- None.
- None.
MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that its Special Meeting of Stockholders (the “Special Meeting”), which was originally scheduled to be held on Thursday, September 11, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on Friday, September 12, 2025), has been postponed. The Special Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/AVR2025SM, on Thursday, September 18, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on Friday, September 19, 2025). The record date for the Special Meeting, August 11, 2025 (the “Record Date”), is unchanged and applies to the postponed Special Meeting.
The Special Meeting has been postponed to provide the Company’s stockholders with additional time to vote in order to facilitate broader participation. The Company’s Board of Directors unanimously recommends that you vote FOR the proposals identified in the Company’s definitive Proxy Statement for the Special Meeting (the “Proxy Statement”), which was filed with the Securities and Exchange Commission (the “SEC”) on August 18, 2025.
Voting Details
If you have already voted your shares of Common Stock or directed CHESS Depositary Nominees Pty Ltd (“CDN”) to vote your CHESS Depositary Interests (“CDIs”) by completing the CDI Voting Instruction Form and you do not desire to change your vote, your prior vote will remain voted without the need for you to take any additional action.
If you held shares of Common Stock on the Record Date and have not yet voted, you may do so now using the directions provided in the Proxy Statement. To ensure that proxies are received in time to be counted prior to the Special Meeting, proxies submitted via the Internet or by telephone should be received by 11:59 p.m. Eastern time on September 17, 2025 (being 1:59 p.m. AEST on September 18, 2025), and proxies submitted by mail should be received by the close of business on September 17, 2025 (being 7:00 a.m. AEST on September 18, 2025).
If you held CDIs on the Record Date and you have not yet directed CDN to vote by completing the CDI Voting Instruction Form, you may submit your completed CDI Voting Instruction Form to Computershare, the agent the Company has designated for the collection and processing of voting instructions from the Company’s CDI holders, prior to 5:00 p.m. Central time on September 16, 2025 (being 8:00 a.m. AEST on September 17, 2025) in accordance with the instructions on the CDI Voting Instruction Form.
Important Additional Information
The Company filed the definitive Proxy Statement with the SEC on August 18, 2025, which should be read in conjunction with this notice. To the extent information in this notice updates or conflicts with information contained in the Proxy Statement, the information in this notice is more current. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY THE COMPANY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT ANY SOLICITATION. Stockholders may obtain a free copy of the Proxy Statement and the other relevant materials, and any other documents filed by the Company with the SEC, at the SEC’s website at https://www.sec.gov or on the “SEC Filings” section of the Company’s website at https://www.anteristech.com/investors.
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (“THV”), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “intend,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, any statements regarding the uncertainties related to the presence of a quorum at the Special Meeting and receipt of stockholder approval of the proposals presented at the Special Meeting. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K filed with the SEC on March 12, 2025, as amended on April 29, 2025, and Quarterly Reports on Form 10-Q filed with the SEC on May 13, 2025 and August 11, 2025. Readers are cautioned not to place undue reliance on forward-looking statements, and except as required by law, the Company does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
| For more information: | |
| Investor Relations | Investor Relations (US) |
| investor@anteristech.com | mchatterjee@bplifesciences.com |
| Debbie Ormsby | Malini Chatterjee, Ph.D. |
| Anteris Technologies Global Corp. | Blueprint Life Science Group |
| +61 1300 550 310 | +61 7 3152 3200 | +1 917 330 4269 |
FAQ
When is the postponed Anteris Technologies (AVR) Special Meeting of Stockholders?
What is the record date for the Anteris Technologies Special Meeting?
How can shareholders vote for the Anteris Technologies Special Meeting?
Where can investors access Anteris Technologies' Proxy Statement materials?
Why did Anteris Technologies postpone their Special Meeting?
